ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1507	National Cancer Institute	Html	en	Extragonadal Germ Cell Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of extragonadal germ cell tumors.	residual mass 0.384023 large tumor volume 0.30085 residual disease. 0.273583 recurrent testicular cancer. 0.3175 cisplatin-based chemotherapy regimens 0.371374 PDQ cancer information 0.391809 bulky tumors 0.328858 nonseminoma germ cell 0.421124 cell tumors. 0.272309 nonseminomatous germ cell 0.40313 clinical trials 0.311324 relatively small tumors 0.373793 germ cells 0.335003 particularly young individuals 0.307507 Initial chemotherapy 0.290755 cancer information summary 0.37005 breast cancer prevention 0.298248 careful testicular examination 0.334354 Initial debulking surgery 0.299396 extragonadal primary tumors 0.367991 patients 0.377174 BEP regimen 0.273424 NCI’s PDQ 0.288373 PDQ Adult Treatment 0.321273	NCI PDQ cancer 0.337916 Craniospinal radiation therapy 0.306681 extragonadal germ cell 0.679693 international germ cell 0.403901 tumor prognostic classification 0.317369 overall survival rates 0.302813 long-term disease-free survival 0.296962 chemotherapy course 0.295979 major clinical trial 0.309884 autologous bone marrow 0.294582 advanced disseminated germ 0.372421 seminomatous germ cell 0.403127 nonseminomatous extragonadal germ 0.370944 testicular seminoma 0.333059 serum alpha fetoprotein 0.309001 high-risk patients 0.281542 larger residual masses 0.321492 National Cancer Institute 0.298826 PDQ documents 0.279503 nonseminoma testicular cancer 0.332786 nonlocalized tumors 0.326576 germ cell tumors 0.92252 residual mass posttreatment 0.32699 Hematologic toxic effects 0.298226	CLICK HERE
1581	National Cancer Institute	Html	en	Thyroid Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of thyroid cancer.	thyroid hormone 0.462109 thyroid cells 0.459144 thyroid hormone levels 0.441028 body 0.475956 thyroid nodules 0.440882 thyroid hormone replacement 0.418097 type 0.402327 PDQ cancer information 0.417269 clinical trial search 0.44196 clinical trials 0.712208 thyroid cancer spreads 0.460066 radioactive iodine therapy 0.447344 cancer information summary 0.398763 clinical trial 0.54371 thyroid disease 0.440863 patients 0.405549 fine-needle aspiration biopsy 0.401121 sentinel lymph node 0.409752 thyroid tumor 0.430395 lymph nodes 0.45279 thyroid cancer cells 0.479847 thyroid cancer treatment 0.491155 radiation therapy 0.478836 medullary thyroid cancer 0.563411 tyrosine kinase inhibitor 0.42467	thyroid scan 0.39797 treatment 0.554504 childhood thyroid cancer 0.480138 thyroid nodule 0.461177 follicular thyroid cells 0.442093 metastatic thyroid cancer 0.461409 healthy thyroid 0.426685 undifferentiated thyroid cancer 0.481926 thyroid cancer 0.866042 cancer cells 0.55043 thyroid tissue 0.43819 familial medullary thyroid 0.436692 anaplastic thyroid cancer 0.503212 National Cancer Institute 0.411413 Thyroid hormones 0.426342 external radiation therapy 0.459156 papillary thyroid cancers 0.4232 differentiated thyroid cancer 0.481235 thyroid uses iodine 0.446079 cancer clinical trials 0.453504 stage 0.433394 tumor 0.440267 cancer 0.979846 information 0.45122	CLICK HERE
1704	National Cancer Institute	Html	en	Psychological Stress and Cancer	A fact sheet that describes the effects of stress on the body, the results of research on the relationship between stress and cancer, and information about coping with stress.	Sood AK 0.622496 cancer treatment 0.603243 primary breast cancer 0.597411 Antoni MH 0.570507 human cancer cells 0.605494 family member 0.588007 psychological distress 0.593032 fact sheet 0.615559 mammary fat pads 0.570769 emotional pressure 0.583244 Health care providers 0.574848 risky behaviors 0.581446 cancer metastasis 0.572171 social support 0.574381 triple-negative breast cancer 0.658004 various psychological factors 0.615469 Lutgendorf SK 0.681275 cancer patients 0.656706 cancer survival 0.572148 stress cause cancer 0.708673 blood sugar levels 0.578812 Clinical Oncology 0.599718 speed heart rate 0.575901 ovarian carcinoma patients 0.577415	higher rates 0.57609 specific psychological conditions 0.622117 Psychological Bulletin 0.579687 elevated tumor norepinephrine 0.576809 psychological stress 0.974362 beta blockers 0.5732 normal life activities 0.583211 physical health problems 0.585785 drinking alcohol 0.576593 cancer outcomes 0.570999 biobehavioral signaling pathways 0.570101 stress management techniques 0.670628 clinical health psychologist 0.575253 Cancer Research 0.5705 stress hormone norepinephrine 0.675379 poorer clinical outcomes 0.584728 stress hormones 0.675405 people 0.602029 certain stress hormones 0.663467 New patient-centered care 0.571423 close family member 0.58133 Related Resources 0.579385 et al 0.674807 Related Resources section 0.573303	CLICK HERE
1804	National Cancer Institute	Html	es	Tratamiento del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama).	Surgical Adjuvant Breast 0.311283 node-positive breast 0.305691 susceptibility to breast 0.306299 results from 0.304936 node-negative breast carcinoma 0.307067 linfáticos internos mamarios 0.304657 invasive breast 0.310223 MammaPrint breast 0.305772 metástasis manifiesta 0.303936 Breast Cancer Family 0.311467 invasive breast carcinoma 0.30652 breast magnetic resonance 0.305716 Breast Cancer Linkage 0.318171 with node-negative breast 0.307174 brca2 mutation 0.31001 early breast 0.305558 Metástasis ipsilateral rodaderab 0.30419 Cancer Linkage Consortium 0.309543 risk factors 0.310931 ganglio centinela 0.304343 mucinous breast carcinomas 0.305818 Natl Cancer Inst 0.352497 breast carcinomas 0.328163 Women's Health Initiative 0.304548 node-negative breast 0.315228	N2b Metástasis 0.303847 from benign breast 0.306434 N2a Metástasis 0.30385 BRCA2 mutation carriers 0.309625 investigation into cancer 0.309168 Bilateral breast carcinoma 0.306729 ganglios positivos.Se 0.305633 Lancet Oncol 0.305043 contralateral breast 0.320411 lobular breast 0.305977 benign breast 0.312903 ganglio linfático centinela 0.333143 ganglios satélites 0.30541 Cancer Staging Manual 0.308858 Cancer Res Treat 0.315484 Clin Oncol 0.389208 breast carcinomas distinguish 0.305804 breast cancer 0.999811 Relat Cancer 0.305724 BRCA2-associated breast 0.305731 with invasive breast 0.307222 family history 0.30714 AJCC Cancer Staging 0.309184 Breast Cancer Res 0.348498	CLICK HERE
1832	National Cancer Institute	Html	es	Tratamiento del cáncer de vagina (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vagina.	Obstet Gynecol 0.283662 Lippincott Williams 0.242575 vagina funcional 0.243946 berek js 0.239666 Carlone M 0.228988 prognostic factors 0.719083 vaginal cancer 0.473271 Sin embargo 0.237061 American Cancer Society 0.229383 Frank SJ 0.247276 Definitive radiotherapy 0.277726 institutional experience 0.233025 Radiat Oncol Biol 0.893767 DeVita VT Jr 0.277942 Camel HM 0.230789 Jhingran A 0.245715 Gynecol Oncol 0.996446 Rosenberg SA 0.240229 primary invasive squamous 0.2365 squamous carcinoma 0.334954 Lee P 0.243278 Galakatos AE 0.229807 vagina treated with 0.406995 primary carcinoma 0.405837 Markman MA 0.223742	estadio ii 0.224737 Seski J 0.269409 vaginal intraepithelial neoplasia 0.27229 Perez CA 0.260508 Wheeler JA 0.267137 Cancer Staging Manual 0.259578 Levenback C 0.24589 Definitive irradiation 0.237883 Chen AS 0.271634 Eifel PJ 0.224915 PDQ Tratamiento 0.250686 New York 0.251038 long-term evaluation 0.231124 9th ed 0.223747 Zagars GK 0.268986 Oncol Biol Phys 0.938039 invasive squamous carcinoma 0.314957 Dundas G 0.228633 Treat Options Oncol 0.229038 cuello uterino 0.451234 Gynecol Cancer 0.242612 Twenty-year review 0.228463 AJCC Cancer Staging 0.261483 squamous cell carcinoma 0.643647	CLICK HERE
1833	National Cancer Institute	Html	es	Tratamiento de los tumores carcinoides gastrointestinales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores carcinoides gastrointestinales.	metastatic carcinoid tumor 0.417651 carcinoides gi 0.793345 enfermedad cardíaca carcinoide 0.432281 carcinoides duodenales 0.478754 células ec 0.425941 tracto gi 0.460962 Sin embargo 0.46213 tumores carcinoides gi 0.491452 PDQ Tumores neuroendocrinos 0.416768 imaging features with 0.416291 células neuroendocrinas gi 0.414118 marcadores carcinoides 0.432817 Exp Clin Cancer 0.413418 Cancer Res 0.421273 Res Clin Endocrinol 0.414031 Clin Gastroenterol 0.414029 síntomas carcinoides 0.431545 Pract Res Clin 0.438075 síndrome carcinoideo 0.506176 Clin Cancer Res 0.414666 patients with 0.502884 carcinoid tumors 0.605663 Best Pract Res 0.431995 Clin Endocrinol Metab 0.422923 carcinoid heart 0.423722	carcinoides celulares cse 0.43559 carcinoide celular cse 0.415154 tumores carcinoides 0.966863 neuroendocrine tumors 0.59007 TNE pancreáticos 0.414445 gastrointestinal tract 0.419836 tumores carcinoides gastrointestinales 0.615452 Surg Pathol 0.422847 Dig Dis Sci 0.415197 tumores tipo 0.415164 multiple endocrine neoplasia 0.418143 CSE tipo 0.414261 TNE GI 0.460772 tumores neuroendocrinos 0.4479 carcinoides esporádicos gi 0.445952 Surg Oncol 0.418143 with von recklinghausen 0.424868 somatostatin receptor 0.413855 neuroendocrine tumour 0.454787 tumores neuroendocrinos pancreáticos 0.419002 carcinoid tumor with 0.413498 Acad Sci 0.415384 gastrointestinal carcinoids 0.415688 tumores duodenales 0.41576	CLICK HERE
1934	National Cancer Institute	Html	es	Tratamiento del osteosarcoma e histiocitoma fibroso maligno óseo (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del osteosarcoma e histiocitoma fibroso maligno óseo.	siguientes procedimientos 0.506474 células madre 0.526262 pequeña cantidad 0.50899 siguientes especialistas 0.504251 siguientes tipos 0.504112 rayos x 0.523233 tejido óseo 0.519779 enlace drugs approved 0.505077 suficiente tejido 0.503088 fibroso maligno óseo 0.821835 efectos tardíos 0.529504 PDQ Efectos tardíos 0.509684 National Cancer Institute 0.502454 siguientes riesgos 0.501964 médula ósea también 0.505126	Instituto Nacional 0.509248 PDQ Tratamiento 0.523403 determinados cambios 0.501954 alta potencia 0.503883 nuevos tipos 0.503233 Physician Data Query 0.509387 cáncer óseo 0.512408 siguientes situaciones 0.505889 Bone Cancer 0.502772 siguientes enlaces 0.502451 células sanguíneas maduras 0.509706 célula madre 0.502683 siguientes pruebas 0.512226 fibroso maligno 0.960799	CLICK HERE
1945	National Cancer Institute	Html	es	Efectos tardíos del tratamiento anticanceroso en la niñez (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de los problemas de salud que aparecen una vez que termina el tratamiento del cáncer.	cancer statistics 0.312893 among adult survivors 0.309342 health insurance 0.30576 childhood leukemia survivors 0.314627 Marrow Transplant Survivor 0.306695 largo plazo 0.353459 Cancer Survivor cohort 0.310798 CA Cancer 0.308516 group long-term follow-up 0.307764 mortality among 5-year 0.309974 health conditions 0.3067 young adult cancers 0.387348 late mortality 0.309117 Ness KK 0.312945 among childhood cancer 0.329959 adult survivors 0.341543 Hudson MM 0.322937 among survivors 0.313213 British Childhood Cancer 0.315849 utilization among long-term 0.306183 childhood cancer 0.973475 cancer survivor study 0.608871 late effects 0.312383 SEER Cancer Statistics 0.308306 long-term survivors 0.338777	health care utilization 0.307102 Survivor Study cohort 0.310239 chronic health conditions 0.305835 among adolescent survivors 0.308292 Care Cancer 0.309376 among 5-year survivors 0.328567 Pediatr Blood Cancer 0.42011 oncology group long-term 0.310223 adolescent cancers 0.313982 efectos tardíos 0.375703 survivors research program 0.306998 report from 0.396085 National Cancer Institute 0.308232 Oeffinger KC 0.306859 health care 0.314251 mortality among survivors 0.308816 Clin Oncol 0.375569 childhood cancer survivor 0.872407 medical care 0.307228 among long-term survivors 0.315379 late mortality among 0.306982 long-term follow-up guidelines 0.320022 Outcomes Among Childhood 0.309917 children's oncology group 0.433388	CLICK HERE
15908	National Cancer Institute	Html	es	Laetrilo (amigdalina) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del laetrilo (amigdalina) como tratamiento para personas con cáncer.	Natl Acad Sci 0.351583 institute's retrospective laetrile 0.328712 treated with laetrile 0.349302 Exp Med Surg 0.328157 Promoting poison 0.33939 antitumor activity 0.465434 cases treated with 0.28668 treatment with laetrile 0.295229 with laetrile 0.90547 CA Cancer 0.770829 Acta Unio Int 0.423146 Cancer Industry 0.474642 Med Hypotheses 0.298922 Cancer Commission 0.379224 Estados Unidos 0.752083 Amygdalin induces apoptosis 0.284053 Navarro MD 0.430756 Unio Int Contr 0.427919 Five years 0.324596 Ellison NM 0.316229 Bickis IJ 0.282987 Acad Med 0.304051 Ames MM 0.502122 Laetrile toxicity studies 0.333014 Med Assoc 0.356472	Diss Abstr Int 0.346583 years experience with 0.456942 Proc Natl Acad 0.355643 vía oral 0.317497 Laetrile toxicity 0.342269 retrospective laetrile analysis 0.331541 Cancer Establishment 0.478533 experience with laetrile 0.549066 Dorr RT 0.337868 Cancer Institute retrospective 0.411789 Unproven methods 0.542254 Treat Rep 0.798281 current status 0.343299 Intern Med 0.566133 Kovach JS 0.535271 with laetrile therapy 0.559394 Clin Nutr 0.378962 Int Contr Cancrum 0.427916 laetrile intoxication 0.281414 Moertel CG 0.440121 Herbert V 0.324024 NCI Laetrile Review 0.334924 Paxinos J 0.340814 Med Chem 0.296011	CLICK HERE
16839	National Cancer Institute	Html	en	Previous NCI Alliance Grantees	The NCI Alliance for Nanotechnology in Cancer has funded a multitude of research and training grants since 2005. Find here a list of all of these high impact projects.	cancer-related nanotechnology research 0.909204 initiative 0.300481 private organizations 0.515908 Focus 0.261214 National Cancer Institute 0.829641	clinical practice 0.510503 clinicians 0.293138 areas 0.260532 NCI Alliance 0.657758 major commitment 0.597371	CLICK HERE